Current issues in blood transfusion for sickle cell disease

Current Opinion in Pediatrics

Volumn 21, Issue 1, 2009, Pages 15-21

  Wahl, Shannon ^a   Quirolo, Keith C ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Alloimmunization; Iron overload; Sickle cell disease; Transfusion

Indexed keywords

HYDROXYUREA;

ACUTE CHEST SYNDROME; ALLOIMMUNIZATION; BLOOD DONOR; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; ERYTHROCYTE TRANSFUSION; EXCHANGE BLOOD TRANSFUSION; GENOTYPE; HUMAN; INFECTION; IRON OVERLOAD; MORBIDITY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SICKLE CELL ANEMIA; STROKE; TREATMENT INDICATION;

ANEMIA, SICKLE CELL; BLOOD GROUPING AND CROSSMATCHING; BLOOD TRANSFUSION; HUMANS; HYPERTENSION, PULMONARY; PEDIATRICS; STROKE; TREATMENT OUTCOME;

EID: 62849129028     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328321882e     Document Type: Review

References (60)

1. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-769.
2. Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995;96:2845-2853.
3. Hagar W, Vichinsky E. Advances in clinical research in sickle cell disease. Br J Haematol 2008;141:346-356.
4. Madel JA, Spivack AP. Surgical management of sickle cell anemia: the use of packed red blood cell transfusions. Ann Intern Med 1958;48:399-406.
5. Cohen A, Schwartz E. Excretion of iron in response to deferoxamine in sickle cell anemia. J Pediatr 1978;92:659-662.
6. Crome P, Moffatt B. IgM lymphocytotoxic antibodies following multiple transfusion. Vox Sang 1971;21:11-20.
7. Hwang LY, Beasley RP, Busch MP, et al. Human immunodeficiency virus seroprevalence among blood product recipients in San Francisco before transfusion. Transfusion 1989;29:113-118.
8. Gross S, Godel JC. Comparative studies of height and weight as a blood volume reference standard in normal children and children with sickle cell anemia. Am J Clin Pathol 1971;55:662-670.
9. Eckman JR. Techniques for blood administration in sickle cell patients. Semin Hematol 2001;38:23-29.
10. Dang NC, Johnson C, Eslami-Farsani M, Haywood LJ. Myocardial injury or infarction associated with fat embolism in sickle cell disease: a report of three cases with survival. Am J Hematol 2005;80:133-136.
11. Johnson CS. Arterial blood pressure and hyperviscosity in sickle cell disease. Hematol Oncol Clin North Am 2005;19:827-837;vi.
12. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001;139:785-789.
13. Strouse JJ, Hulbert ML, DeBaun MR, et al. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics 2006;118:1916-1924.
14. Telen MJ. Principles and problems of transfusion in sickle cell disease. Semin Hematol 2001;38:315-323.
15. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
16. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000;342:1855-1865.
17. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995;333:206-213.
18. Styles LA, Abboud M, Larkin S, et al. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol 2007;136:343-344.
19. Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatr 1994;125:909-911.
20. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007;22:106-175.
21. Afenyi-Annan A, Willis MS, Konrad TR, Lottenberg R. Blood bank management of sickle cell patients at comprehensive sickle cell centers. Transfusion 2007;47:2089-2097.
22. Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol 2001;38:14-22.
23. Quirolo K. Transfusion therapy in pediatric sickle cell disease. Blood Ther Med 2006;5:99-108.
24. Singer ST, Quirolo K, Nishi K, et al. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher 1999;14:122-125.
25. Raj A, Bertolone S, Bond S, et al. Cathlink 20: a subcutaneous implanted central venous access device used in children with sickle cell disease on longterm erythrocytapheresis - a report of low complication rates. Pediatr Blood Cancer 2005;44:669-672.
26. Abdul-Rauf A, Gauderer M, Chiarucci K, Berman B. Long-term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications. J Pediatr Hematol Oncol 1995;17:342-345.
27. McCready CE, Doughty HA, Pearson TC. Experience with the Port-A-Cath in sickle cell disease. Clin Lab Haematol 1996;18:79-82.
28. Jeng MR, Feusner J, Skibola C, Vichinsky E. Central venous catheter complications in sickle cell disease. Am J Hematol 2002;69:103-108.
29. Wagner SC, Eschelman DJ, Gonsalves CF, et al. Infectious complications of implantable venous access devices in patients with sickle cell disease. J Vasc Interv Radiol 2004;15:375-378.
30. Evans J, Saba Z, Rosenfeld H, et al. Aortic laceration secondary to palmaz stent placement for treatment of superior vena cava syndrome. Catheter Cardiovasc Interv 2000;49:160-162.
31. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37-43.
32. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990;76:1431-1437.
33. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41:1086-1092.
34. Ambruso DR, Githens JH, Alcorn R, et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987;27:94-98.
35. Tahhan HR, Holbrook CT, Braddy LR, et al. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 1994;34:562-569.
36. Olujohungbe A, Hambleton I, Stephens L, et al. Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol 2001;113:661-665.
37. Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005;129:190-193.
38. Petz LD. Bystander immune cytolysis. Transfus Med Rev 2006;20:110-140.
39. Petz LD, Calhoun L, Shulman IA, et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion 1997;37:382-392.
40. Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion 2006;46:105-110.
41. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008;112:2617-2626.
42. Kleinman SH, Busch MP. The risks of transfusion-transmitted infection: direct estimation and mathematical modelling. Baillieres Best Pract Res Clin Haematol 2000;13:631-649.
43. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev 2005;18:195-204.
44. Fung EB, Harmatz PR, Milet M, et al. Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 2008;43:162-168.
45. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96:76-79.
46. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-1884.
47. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008;10:12.
48. Hillyer CD, Shaz BH, Winkler AM, Reid M. Integrating molecular technologies for red blood cell typing and compatibility testing into blood centers and transfusion services. Transfus Med Rev 2008;22:117-132.
49. Zimring JC, Spitalnik SL, Roback JD, Hillyer CD. Transfusion-induced auto-antibodies and differential immunogenicity of blood group antigens: a novel hypothesis. Transfusion 2007;47:2189-2196.
50. Castilho L, Rios M, Bianco C, et al. DNA-based typing of blood groups for the management of multiply-transfused sickle cell disease patients. Transfusion 2002;42:232-238.
51. Westhoff CM. Molecular testing for transfusion medicine. Curr Opin Hematol 2006;13:471-475.
52. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am 2008;55:483-501;x.
53. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-3632.
54. Zimmerman SA, Schulte WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007;110:1043-1047.
55. Hankins J, Hinds P, Day S, et al. Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr Blood Cancer 2007;48:705-710.
56. Vigneron C, Smani Y, Faivre B. Blood substitutes: state of the art and technical setbacks and why we are still disappointed. Bull Acad Natl Med 2007;191:837-847; discussion 847.
57. Stefan DC, Uys R, Wessels G. Hemopure transfusion in a child with severe anemia. Pediatr Hematol Oncol 2007;24:269-273.
58. Fitzpatrick CM, Savage SA, Kerby JD, et al. Resuscitation with a blood substitute causes vasoconstriction without nitric oxide scavenging in a model of arterial hemorrhage. J Am Coll Surg 2004;199:693-701.
59. Quirolo K. Hemoglobin-based oxygen carriers: a long road from bench to bedside. Pediatr Hematol Oncol 2007;24:461-463.
60. Hagar RW, Michlitsch JG, Gardner J, et al. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol 2008;140:104-112.